medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2005, Number 1

<< Back Next >>

Ann Hepatol 2005; 4 (1)

Alcoholic liver disease. An update

Méndez-Sánchez N, Almeda-Valdés P, Uribe M

Language: English
References: 86
Page: 32-42
PDF size: 207.59 Kb.


Text Extraction

The prevalence and incidence of alcoholic liver disease are constantly evolving. Alcoholic liver disease has a wide clinical spectrum. It may progress to cirrhosis and to end-stage liver disease requiring liver transplantation. The histological manifestations range from steatosis without inflammation to liver cell injury and ultimately to fibrosis and cirrhosis. In some cases, the histological manifestation is steatohepatitis, morphologically characterized by inflammation and necrosis. Currently, although there are no specific tests to establish a diagnosis of steatohepatitis, some serological, radiological, or laboratory tests may be useful. Liver biopsy is useful in confirming a suspected diagnosis and in assessing the extent of parenchymal damage. This review synthesizes the main aspects of the epidemiology, pathogenesis, morphological characteristics, diagnosis, treatment, and prognosis of alcoholic liver disease.


REFERENCES

  1. Corrao G, Ferrari P, Zambon A, Torchio P. Are the recent trends in liver cirrhosis mortality affected by the changes in alcohol consumption? Analysis of latency period in European countries. J Stud Alcohol 1997; 58: 486-494.

  2. Bellentani S, Saccoccio G, Costa G, Tiribelli C, Manenti F, Sodde M, Saveria Croce L, Sasso F, Pozzato G, Cristianini G, Brandi G. Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group. Gut 1997; 41: 845-850.

  3. Dawson DA, Grant BF, Chou SP, Pickering RP. Subgroup variation in U.S. drinking patterns: results of the 1992 national longitudinal alcohol epidemiologic study. J Subst Abuse 1995; 7: 331-344.

  4. Robertson I. Safe drinking. BMJ 1994; 308: 346.

  5. Campollo O, Martínez MD, Valencia JJ, Segura-Ortega J. Drinking patterns and beverage preferences of liver cirrhosis patients in Mexico. Subst Use Misuse 2001; 36: 387-398.

  6. Rehm J, Rehn N, Room R, Monteiro M, Gmel G, Jernigan D, Frick U. The global distribution of average volume of alcohol consumption and patterns of drinking. Eur Addict Res 2003; 9: 147-156.

  7. Méndez-Sánchez N, Uribe M. Conceptos actuales en hepatología. Masson Doyma México. 2003: 259-264.

  8. Saunders JB, Aasland OG, Amundsen A, Grant M. Alcohol consumption and related problems among primary health care patients: WHO collaborative project on early detection of persons with harmful alcohol consumption—I. Addiction 1993; 88: 349-362.

  9. Mendez-Sanchez N, Aguilar-Ramirez JR, Reyes A, Dehesa M, Juarez A, Castaneda B, Sanchez-Avila F, Poo JL, Guevara Gonzalez L, Lizardi J, Valdovinos MA, Uribe M, Contreras AM, Tirado P, Aguirre J, Rivera-Benitez C, Santiago-Santiago R, Bosques-Padilla F, Munoz L, Guerrero A, Ramos M, Rodriguez-Hernandez H, Jacobo-Karam J. Grupo de Estudio, Asociación Mexicana de Hepatologia. Etiology of liver cirrhosis in Mexico. Ann Hepatol 2004; 3: 30-33.

  10. Méndez-Sánchez N, Villa AR, Sánchez-Lara K, Chávez-Tapia NC, Almeda-Valdés P, Ramos-Ostos M, Uribe M. Estimación y proyección (2005-2050) de la prevalencia de enfermedades del hígado en México a través de la mortalidad. Rev Gastroenterol Mex (Abstract). 2004; 69: 290.

  11. Kim WR, Brown RS Jr, Terrault NA, El-Serag H. Burden of liver disease in the United States: summary of a workshop. Hepatology 2002; 36: 227-242.

  12. Leevy CM. Fatty liver: a study of 270 patients with biopsy proven fatty liver and review of the literature. Medicine 1962; 41: 249-276.

  13. Sorensen TI, Orholm M, Bentsen KD, Hoybye G, Eghoje K, Christoffersen P. Prospective evaluation of alcohol abuse and alcoholic liver injury in men as predictors of development of cirrhosis. Lancet 1984; 2: 241-244.

  14. Teli MR, Day CP, Burt AD, Bennett MK, James OF. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet 1995; 346: 987-990.

  15. McCullough AJ, O´Connor JF. Alcoholic liver disease: proposed recommendations for the American College of Gastroenterology. Am J Gastroenterol 1998; 93: 2022-2036.

  16. Brady KT, Randall CL. Gender differences in substance use disorders. Psychiatr Clin North Am 1999; 22: 241-252.

  17. Blume SB. Women and alcohol. A review. JAMA 1986; 256: 1467-1470.

  18. Norton R, Batey R, Dwyer T, MacMahon S. Alcohol consumption and the risk of alcohol related cirrhosis in women. Br Med J (Clin Res Ed) 1987; 295: 80-82.

  19. Adams WL, Yuan Z, Barboriak JJ, Rimm AA. Alcohol-related hospitalizations of elderly people. Prevalence and geographic variation in the United States. JAMA 1993; 270: 1222-1225.

  20. Stinson FS, Grant BF, Dufour MC. The critical dimension of ethnicity in liver cirrhosis mortality statistics. Alcohol Clin Exp Res 2001; 25: 1181-1187.

  21. Caetano R, Kaskutas LA. Changes in drinking patterns among whites, blacks and Hispanics, 1984-1992. J Stud Alcohol 1995; 56: 558-565.

  22. Degos F. Hepatitis C and alcohol. J Hepatol 1999; 31 Suppl 1: 113-118.

  23. Ostapowicz G, Watson KJ, Locarnini SA, Desmond PV. Role of alcohol in the progression of liver disease caused by hepatitis C virus infection. Hepatology 1998; 27: 1730-1735.

  24. Mendenhall CL, Anderson S, Weesner RE, Goldberg SJ, Crolic KA. Protein-calorie malnutrition associated with alcoholic hepatitis. Veterans Administration Cooperative Study Group on Alcoholic Hepatitis. Am J Med 1984; 76: 211-222.

  25. Suter PM, Schutz Y, Jequier E. The effect of ethanol on fat storage in healthy subjects. N Engl J Med 1992; 326: 983-987.

  26. Cravo ML, Gloria LM, Selhub J, Nadeau MR, Camilo ME, Resende MP, Cardoso JN, Leitao CN, Mira FC. Hyperhomocysteinemia in chronic alcoholism: correlation with folate, vitamin B-12, and vitamin B-6 status. Am J Clin Nutr 1996; 63: 220-224.

  27. Reuler JB, Girard DE, Cooney TG. Current concepts. Wernicke´s encephalopathy. N Engl J Med 1985; 312: 1035-1039.

  28. Leo MA, Lieber CS. Hepatic vitamin A depletion in alcoholic liver injury. N Engl J Med 1982; 307: 597-601.

  29. Tsukamoto H, Lu SC. Current concepts in the pathogenesis of alcoholic liver injury. FASEB J 2001; 15: 1335-1349.

  30. Colell A, García-Ruiz C, Miranda M, Ardite E, Mari M, Morales A, Corrales F, Kaplowitz N, Fernandez-Checa JC. Selective glutathione depletion of mitochondria by ethanol sensitizes hepatocytes to tumor necrosis factor. Gastroenterology 1998; 115: 1541-1551.

  31. Cahill A, Stabley GJ, Wang X, Hoek JB. Chronic ethanol consumption causes alterations in the structural integrity of mitochondrial DNA in aged rats. Hepatology 1999; 30: 881-888.

  32. McCullough AJ, Bugianesi E, Marchesini G, Kalhan SC. Gender-dependent alterations in serum leptin in alcoholic cirrhosis. Gastroenterology 1998; 115: 947-953.

  33. Sarphie TG, D´Souza NB, Spitzer JJ, Deaciuc IV. Chronic alcohol feeding in liquid diet or in drinking water has similar effects on electron microscopic appearance of the hepatic sinusoid in the rat. Alchol. Clin Exp Res 1996; 20: 973-979.

  34. Nanji AA, Griniuviene B; Yacoub LK, Fogt F, Tahan SR. Intercellular adhesion molecule-1 expression in experimental alcoholic liver disease: relationship to endotoxemia and TNF alpha messenger RNA. Exp Mol Pathol 1995; 62: 45-51.

  35. Nieto N, Friedman SL, Greenwel P, Cederbaum AI. CYP2E1-mediated oxidative stress induces collagen type I expression in rat hepatic stellate cells. Hepatology 1999; 30: 987-996.

  36. Higuchi S, Matsushita S, Muramatsu T, Murayama M, Hayashida M. Alcohol and aldehyde dehydrogenase genotypes and drinking behavior in Japanese. Alcohol Clin Exp Res 1996; 20: 493-497.

  37. MacSween RN, Burt AD. Histologic spectrum of alcoholic liver disease. Semin Liver Dis 1986; 6: 221-232.

  38. Baptista A, Bianchi L, de Groole. Alcoholic liver disease: morphological manifestations. Review by an international group. Lancet 1981; 1: 707-711.

  39. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 2001: 21: 3-16.

  40. MacSween RN, Burt AD. Histologic spectrum of alcoholic liver disease. Semin Liver Dis 1986; 6: 221-232.

  41. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon Br. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-2474.

  42. Takahashi T, Kamimura T, Ichida F. Ultrastructural findings on polymorphonuclear leucocyte infiltration and acute hepatocellular damage in alcoholic hepatitis. Liver 1987; 7: 347-358.

  43. French SW, Nash J, Shitabata P, Kachi K, Hara C, Chedid A, Mendenhall CL. Pathology of alcoholic liver disease. VA Cooperative Study Group. Semin Liver Dis 1993; 13: 154-169.

  44. Goodman ZD, Ishak KG. Occlusive venous lesions in alcoholic liver disease. A study of 200 cases. Gastroenterology 1982; 83: 786-796.

  45. Becker U, Deis A, Sorensen TI, Gronbaek M, Borch-Johnsen K, Muller CF, Schnohr P, Jensen G. Prediction of risk of liver disease by alcohol, intake, sex, and age: a prospective population study. Hepatology 1996; 23: 1025-1029.

  46. Hoeksema HL, de Bock GH. The value of laboratory tests for the screening and recognition of alcohol abuse in primary care patients. J Fam Pract 1993; 37: 268-276.

  47. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR), 4th ed. Washington, D. C.: American Psychiatric Association; 2000.

  48. Mendenhall CL. Alcoholic hepatitis. Clin Gastroenterol 1981; 10: 417-441.

  49. Williams AL, Hoofnagle JH. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. Gastroenterology 1988; 95: 734-739.

  50. Orrego H, Blake JE, Blendis LM, Medline A. Prognosis of alcoholic cirrhosis in the presence and absence of alcoholic hepatitis. Gastroenterology 1987; 92: 208-214.

  51. Tanaka T, Yabusako T, Yamashita T, Kondo K, Nishiguchi S, Kuroki T, Monna T. Contribution of hepatitis C virus to the progression of alcoholic liver disease. Alcohol Clin Exp Res 2000; 24(4 Suppl): 112S-116S.

  52. DiMartini A, Day N, Lane T, Beisler AT, Dew MA, Anton R. Carbohydrate deficient transferrin in abstaining patients with end-stage liver disease. Alcohol Clin Exp Res 2001; 25: 1729-1733.

  53. Uppal R, Rosman A, Hernandez R, Baraona E, Lieber CS. Effects of liver disease on red blood cell acetaldehyde in alcoholics and non-alcoholics. Alcohol Alcohol Suppl 1991; 1: 323-326.

  54. Pessione F, Ramond MJ, Peters L, Pham BN, Batel P, Rueff B, Valla DC. Five-year survival predictive factors in patients with excessive alcohol intake and cirrhosis. Effect of alcoholic hepatitis, smoking and abstinence. Liver Int 2003; 23: 45-53.

  55. Mendenhall CL, Moritz TE, Roselle GA, Morgan TR, Nemchausky BA, Tamburro CH, Schiff ER, McClain CJ, Marsano LS, Allen JI. A study of oral nutritional support with oxandrolone in malnourished patients with alcoholic hepatitis: results of a Department of Veterans Affairs cooperative study. Hepatology 1993; 17: 564-576.

  56. Soberon S, Pauley MP, Duplantier R, Fan A, Halsted CH. Metabolic effects of enteral formula feeding in alcoholic hepatitis. Hepatology 1987; 7: 1204-1209.

  57. Nompleggi DJ, Bonkovsky HL. Nutritional supplementation in chronic liver disease: an analytical review. Hepatology 1994; 19: 518-533.

  58. Marchesini G, Bianchi G, Merli M, Amodio P, Panella C, Loguercio C, Rossi Fanelli F, Abbiati R. Italian BCAA Study Group. Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. Gastroenterology 2003; 124: 1792-1801.

  59. Raynard B, Balian A, Fallik D, Capron F, Bedossa P, Chaput JC, Naveau S. Risk factors of fibrosis in alcohol-induced liver disease. Hepatology. 2002;35:635-638.

  60. Colell A, Garcia-Ruiz C, Morales A, Ballesta A, Ookhtens M, Rodes J, Kaplowitz N, Fernandez-Checa JC. Transport of reduced glutathione in hepatic mitochondria and mitoplasts from ethanol-treated rats: effect of membrane physical properties and S-adenosyl-L-methionine. Hepatology. 1997;26:699-708.

  61. Watson WH, Zhao Y, Chawla RK. S-adenosyl-methionine attenuates the lipopolysaccharide-induced expression of the gene for tumour necrosis factor alpha. Biochem J 1999; 342(Pt 1): 21-25.

  62. Brady LM, Fox ES, Fimmel CJ. Polyenylphosphatidylcholine inhibits PDGF-induced proliferation in rat hepatic stellate cells. Biochem Biophys Res Commun 1998; 248: 174-179.

  63. Aleynik MK, Leo MA, Aleynik SI, Lieber CS. Polyenylphosp hatidylcholine opposes the increase of cytochrome P-4502E1 by ethanol and corrects its iron-induced decrease. Alcohol Clin Exp Res 1999; 23: 96-100.

  64. Rai RM, Loffreda S, Karp CL, Yang SQ, Lin HZ, Diehl AM. Kupffer cell depletion abolishes induction of interleukin-10 and permits sustained overexpression of tumor necrosis factor alpha messenger RNA in the regenerating rat liver. Hepatology 1997; 25: 889-895.

  65. Maddrey WC, Boitnott JK, Bedine MS, Weber FJ Jr, Mezey E, White RI Jr. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978; 75: 193-199.

  66. McClain CJ, Barve S, Deaciuc I, Hill DB. Tumor necrosis factor and alcoholic liver disease. Alcohol Clin Exp Res 1998; 22: 248S-252S.

  67. Imperiale TF, McCullough AJ. Do corticosteroids reduce mortality from alcoholic hepatitis? A meta-analysis of the randomized trials. Ann Intern Med 1990; 113: 299-307.

  68. Ramond MJ, Poynard T, Rueff B, Mathurin P, Theodore C, Chaput JC, Benhamou JP. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med 1992; 326: 507-512.

  69. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119: 1637-1648.

  70. Rambaldi A, Gluud C. Propylthiouracil for alcoholic liver disease. Cochrane Database Syst Rev 2002; CD002800.

  71. Murphy F, Arthur M, Iredale J. Developing strategies for liver fibrosis treatment. Expert Opin Investig Drugs 2002; 11: 1575-1585.

  72. Neuberger J, Schulz KH, Day C, Fleig W, Berlakovich GA, Berenguer M, Pageaux GP, Lucey M, Horsmans Y, Burroughts A, Hockerstedt K. Transplantation for alcoholic liver disease. J Hepatol 2002; 36: 130-137.

  73. Howard L, Fahy T, Wong P. Sherman D, Gane E, Williams R. Psychiatric outcome in alcoholic liver transplant patients. QJM 1994; 87: 731-736.

  74. Keeffe BG, Valantine H, Keeffe EB. Detection and treatment of coronary artery disease in liver transplant candidates. Liver Transpl 2001; 7: 755-761.

  75. Fabrega E, Crespo J, Casafont F, De las Heras G, de la Pena J, Pons-Romero F. Alcoholic recidivism after liver transplantation for alcoholic cirrhosis. J Clin Gastroenterol 1998; 26: 204-206.

  76. Diehl AM. Alcoholic liver disease: natural history. Liver Transpl Surg 1997; 3: 206-211.

  77. Sato N, Lindros KO, Baraona E, Ikejima K, Mezey E, Jarvelainen HA, Ramchandani VA. Sex difference in alcohol-related organ injury. Alcohol Clin Exp Res 2001; 25 (5 Suppl ISBRA): 40S-45S.

  78. Schenker S. Medical consequences of alcohol abuse: is gender a factor? Alcohol Clin Exp Res 1997; 21: 179-181.

  79. Li TK, Beard JD, Orr WE, Kwo PY, Ramchandani VA, Thomasson HR. Variation in ethanol pharmacokinetics and perceived gender and ethnic differences in alcohol elimination. Alcohol Clin Exp Res 2000; 24: 415-416.

  80. Naveau S, Giraud V, Borotto E, Aubert A, Capron F, Chaput JC. Excess weight risk factor for alcoholic liver disease. Hepatology 1997; 25: 108-111.

  81. Yang SQ, Lin HZ, Lane MD, Clemens M, Diehl AM. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci USA 1997; 94: 2557-2562.

  82. Jarvelainen HA, Orpana A, Perola M, Savolainen VT; Karhunen PJ, Lindros KO. Promoter polymorphism of the CD14 endotoxin receptor gene as risk factor for alcoholic liver disease. Hepatology 2001; 33: 1148-1153.

  83. Marbet UA, Bianchi L, Meury U, Stalder, GA. Long-term histological evaluation of the natural history and prognostic factors of alcoholic liver disease. J Hepatol 1987; 4: 364-372.

  84. Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, Kremers W, Lake J, Howard T, Merion RM, Wolfe RA, Krom R, United Network for Organ Sharing Liver Disease Severity Score Committee. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124: 91-96.

  85. Dunn W, Jamil LH, Brown LS, Wiesner RH, Kim WR, Menon KV, Malinchoc M, Kamath PS, Shah V. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology 2005; 41: 353-358.

  86. Donato F, Tagger A, Gelatti U, Parrinello G, Boffetta P, Albertini A, Decarli A, Trevisi P, Ribero ML, Martelli C. Porru S, Nardi G. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 2002; 155: 323-331.




2020     |     www.medigraphic.com